|Table of Contents|

Research progress of liquid biopsy in early diagnosis of breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 19
Page:
3710-3714
Research Field:
Publishing date:

Info

Title:
Research progress of liquid biopsy in early diagnosis of breast cancer
Author(s):
GENG Yaxing; LI Yuhui; HUANG Guomin
Department of Thyroid and Breast Surgery,Xinmin on Campus,China-Japan Union Hospital of Jilin University,Jilin Changchun 130012,China.
Keywords:
breast cancer; liquid biopsy; early diagnosis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.19.036
Abstract:
Breast cancer is the most common female malignant tumor.Early diagnosis of breast cancer is lack of tumor markers with high sensitivity and specificity.In clinical work,most patients are diagnosed because of breast mass.The course of disease is often in the middle and late stage of progression,which affects the treatment opportunity and prognosis of patients.With the development and progress of corresponding disciplines and technologies,liquid biopsy technology with its technical advantages has rapidly become a research hotspot,showing the great potential clinical application value and prospect,which opens a new way for early diagnosis of breast cancer.In this paper,we reviewed the new progress of tumor markers such as circulating tumor DNA（ctDNA),circulating tumor cells（CTCs),exosomes,tumor-educated platelets(TEPs) and other tumor markers in the early diagnosis of breast cancer.

References:

［1］谭斌斌,向迪,贾蒙,等.代谢组学在乳腺癌生物标志物研究中的现状及展望［J］.中国科学:生命科学,2018,48（1):15-23. TAN BB,XIANG D,JIA M,et al.Current situation and prospect of metabonomics in breast cancer biomarkers research［J］.Chinese Science:Life Sciences,2018,48（1):15-23.
［2］汤鸿超,孟旭莉.乳腺癌相关长链非编码RNA的研究进展［J］.基础医学与临床,2016,36(12):1738-1742. TANG HC,MENG XL.Research progress of breast cancer related long non coding RNA［J］.Basic Medicine and Clinical,2016,36（12):1738-1742.
［3］宋宏伟,丛辉.ADAMTS9-AS2在乳腺癌患者血浆中的表达及其意义［J］.检验医学与临床,2019,16（4):464-466,470. SONG HW,CONG H.Expression and significance of ADAMTS9-AS2 in plasma of patients with breast cancer［J］.Laboratory medicine and clinical,2019,16（4):464-466,470.
［4］NELSON HD,FU R,CANTOR A,et al.Effectiveness of breast cancer screening:Systematic review and Meta-analysis to update the 2009 U.S. preventive services task force recommendation［J］.Annals of Internal Medicine,2016,164(4)：244-255.
［5］陈丽婷,周剑峰.液体活检在肿瘤临床精准诊断和预后判断中的应用［J］.内科急危重症杂志,2017,23（2):99-101. CHEN LT,ZHOU JF.Application of liquid biopsy in clinical accurate diagnosis and prognosis judgment of tumor［J］.Journal of Internal Medicine,2017,23（2):99-101.
［6］KUHN T,FLOEGEL A,SOOKTHAI D,et al.Higher plasma levels of lysophosphatidylcholine 18∶0 are related to a lower risk of common cancers in a prospective metabolomics study［J］.BMC Medicine,2016,14(1)：13.
［7］陈琛,谢长宽,冯江涛.乳腺癌肿瘤标志物在分子诊断中的作用［J］.世界最新医学信息文摘,2018,18(68):109-110. CHEN C,XIE CK,FENG JT.The role of tumor markers in molecular diagnosis of breast cancer［J］.World latest Medical Information Abstracts,2018,18（68):109-110.
［8］王传新.肿瘤液体活检［J］.山东大学学报（医学版）,2021,59(9):64-71. WANG CX.Liquid biopsy of tumor［J］.Journal of Shandong University（Health Science),2021,59（9):64-71.
［9］周斌,辛灵,徐玲,等.乳腺癌液体活检的现状与前景［J］.中华外科杂志,2018,56（2):106-109. ZHOU B,XIN L,XU L,et al.Current situation and prospect of liquid biopsy of breast cancer［J］.Chinese Journal of Surgery,2018,56（2):106-109.
［10］刁志宏,黄海霞.液体活检在肿瘤中的应用［J］.医学综述,2018,24(18):3603-3607,3612. DIAO ZH,HUANG HX.Application of liquid biopsy in tumor［J］.Medical review,2018,24（18):3603-3607,3612.
［11］郭远薇,胡政,罗伟濠,等.循环肿瘤标志物在乳腺癌复发和预后评估中的研究进展［J］.中国癌症防治杂志,2019,11（2):178-182. GUO YW,HU Z,LUO WH,et al.Research progress of circulating tumor markers in breast cancer recurrence and prognosis evaluation［J］.Chinese Journal of Cancer Prevention and Treatment,2019,11（2):178-182.
［12］金泽宇,陈小松.循环肿瘤DNA在乳腺癌诊治中应用的研究［J］.外科理论与实践,2018,23（5):473-476. JIN ZY,CHEN XS.Study on the application of circulating tumor DNA in the diagnosis and treatment of breast cancer［J］.Surgical Theory and Practice,2018,23（5):473-476.
［13］赵丽娜,李鹏飞,蔡莉,等.转移性乳腺癌循环肿瘤细胞的上皮间质转化水平对化疗疗效的预测意义［J］.临床肿瘤学杂志,2012,17(11):971-975. ZHAO LN,LI PF,CAI L,et al.Predictive significance of epithelial mesenchymal transition level of circulating tumor cells in metastatic breast cancer on chemotherapy efficacy［J］.Journal of Clinical Oncology,2012,17（11):971-975.
［14］王文娜,马飞,徐兵河.循环肿瘤DNA应用于乳腺癌的潜在价值探索［J］.癌症进展,2016,14(10):933-937,943. WANG WN,MA F,XU BH.Exploration of potential value of circulating tumor DNA in breast cancer［J］.Cancer Progress,2016,14（10):933-937,943.
［15］刘翾,李映良,仲罗平,等.循环肿瘤DNA在乳腺癌中的研究进展［J］.癌症进展,2019,17(10):1126-1129,1173. LIU X,LI YL,ZHONG LP,et al.Research progress of circulating tumor DNA in breast cancer［J］.Cancer Progress,2019,17（10):1126-1129,1173.
［16］汪忠淼.TE与TEC新辅助化疗方案对乳腺癌患者外周血CTCs及TSCs的影响［J］.河北医学,2017,23（2):204-208. WANG ZM.Effect of TE and Tec neoadjuvant chemotherapy on peripheral blood CTCs and TSCs in breast cancer patients［J］.Hebei Medical Journal,2017,23（2):204-208.
［17］STOETZER OJ,FERSCHING DM,SALAT C,et al.Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes,DNAse,cytokeratin-18 fragments and survivin［J］.Cancer Letters,2013,336(1)：140-148.
［18］季福庆,李梦婓,印玉龙,等.乳腺癌患者CTCs、ctDNA检测及其诊断价值研究［J］.海南医学,2020,31（7):838-841. JI FQ,LI MF,YIN YL,et al.Detection and diagnostic value of CTCS and ctDNA in patients with breast cancer［J］.Hainan Medical Journal,2020,31（7):838-841.
［19］YOSHINAMI T,KAGARA N,MOTOOKA D,et al.Detection of ctDNA with personalized molecular barcode NGS and its clinical significance in patients with early breast cancer［J］.Translational Oncology,2020,13(8)：100787.
［20］孙浩,张红艳,蒋紫欣.中国地区ctDNA对乳腺癌诊断价值的Meta分析［J］.国际检验医学杂志,2019,40(14):1741-1745. SUN H,ZHANG HY,JIANG ZX.A Meta-analysis of the diagnostic value of ctDNA in breast cancer in China［J］.International Journal of Laboratory Medicine,2019,40（14):1741-1745.
［21］徐健,夏添松.循环肿瘤细胞在乳腺癌个体化治疗中的作用［J］.中国肿瘤外科杂志,2019,11（4):292-295. XU J,XIA TS.The role of circulating tumor cells in individualized treatment of breast cancer［J］.Chinese Journal of Oncology Surgery,2019,11（4):292-295.
［22］何琪杨.肿瘤异质性与抗肿瘤靶向药物的耐药性［J］.药学学报,2016,51（2):197-201. HE QY.Tumor heterogeneity and drug resistance of anti-tumor targeted drugs［J］.Acta Pharmacologica Sinica,2016,51（2):197-201.
［23］CHEN XX,BAI F.Single-cell analyses of circulating tumor cells［J］.Cancer Biology &Amp Medicine,2015,12（3):184-192.
［24］王玉洁,国霞,王晓飞.乳腺癌循环肿瘤细胞检测方法及临床应用［J］.中华临床实验室管理电子杂志,2017,5（2):78-80. WANG YJ,GUO X,WANG XF.Detection method and clinical application of circulating tumor cells in breast cancer［J］.Chinese Journal of Clinical Laboratory Management,2017,5（2):78-80.
［25］PARK HA,BROWN SR,KIM Y.Cellular mechanisms of circulating tumor cells during breast cancer metastasis［J］.International Journal of Molecular Sciences,2020,21(14)：5040.
［26］王建,邵荣金,龚伟达.循环肿瘤细胞研究进展［J］.中国肿瘤外科杂志,2019,11(2):141-145. WANG J,SHAO RJ,GONG WD.Research progress of circulating tumor cells［J］.Chinese Journal of Tumor Surgery,2019,11（2):141-145.
［27］李刚强,许珺,濮亚斌,等.乳腺癌患者外周血中循环肿瘤细胞的检测及临床意义［J］.现代肿瘤医学,2019,27(12):2114-2117. LI GQ,XU J,PU YB,et al.Detection and clinical significance of circulating tumor cells in peripheral blood of patients with breast cancer［J］.Modern Oncology,2019,27（12):2114-2117.
［28］THILL M,LIEDTKE C,AGO BREAST COMMITTEE.AGO recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer:Update 2016［J］.Breast Care（Basel,Switzerland),2016,11(3):216-222.
［29］方超,周总光.循环肿瘤细胞检测方式及临床应用［J］.中华结直肠疾病电子杂志,2019,8（5):501-504. FANG C,ZHOU ZG.Detection methods and clinical application of circulating tumor cells［J］.Chinese Journal of Colorectal Diseases,2019,8（5):501-504.
［30］华红,郝贵亮,王清玲,等.外周血循环肿瘤细胞监测在乳腺癌术后转移早期诊断中的应用［J］.山东医药,2019,59(11):56-58. HUA H,HAO GL,WANG QL,et al.Application of peripheral blood circulating tumor cell monitoring in early diagnosis of breast cancer postoperative metastasis［J］.Shandong Medical Journal,2019,59（11):56-58.
［31］BAHRAMI A,ALEDAVOOD A,ANVARI K,et al.The prognostic and therapeutic application of microRNAs in breast cancer:Tissue and circulating microRNAs［J］.Journal of Cellular Physiology,2018,233(2)：774-786.
［32］VADER P,BREAKEFIELD XO,WOOD MJ.Extracellular vesicles:Emerging targets for cancer therapy［J］.Trends in Molecular Medicine,2014,20(7)：385-393.
［33］HE M,ZENG Y.Microfluidic exosome analysis toward liquid biopsy for cancer［J］.Journal of Laboratory Automation,2016,21(4):599-608.
［34］陈芳,马方婧,迪丽米娜?伊拉木,等.外泌体在乳腺癌中的研究进展［J］.医学综述,2019,25(17):3400-3404,3410. CHEN F,MA FJ,DELIMINA I,et al.Research progress of exosomes in breast cancer［J］.Medical Review,2019,25（17):3400-3404,3410.
［35］KOSAKA N，TAKESHITA F，YOSHIOKA Y，et al.Exosomal tumor-suppressive microRNAs as novel cancer therapy "Exocure" is another choice for cancer treatment［J］.Adv Drug Deliv Rev,2013,65(3):376-382.
［36］刘艳,戴鹏,朱运峰.外泌体作为肿瘤标志物的研究进展［J］.中国生物工程杂志,2019,39（8):74-79. LIU Y,DAI P,ZHU YF.Research progress of exosomes as tumor markers［J］.Chinese Journal of Bioengineering,2019,39（8):74-79.
［37］NEVIANI P，FABBRI M.Exosomic microRNAs in the tumor microenvironment［J］.Front Med（Lausanne),2015,2:47.
［38］胡仁杰,张新宇.外泌体在癌症诊治中的作用与机制［J］.现代肿瘤医学,2019,27(12):2220-2223. HU RJ,ZHANG XY.The role and mechanism of exosomes in the diagnosis and treatment of cancer［J］.Modern Oncology,2019,27（12):2220-2223.
［39］钟国斌,韦薇,周晓,等.外泌体作为浸润性乳腺癌诊断标志物的研究进展［J］.重庆医学,2018,47(33):4278-4281. ZHONG GB,WEI W,ZHOU X,et al.Research progress of exosomes as diagnostic markers of invasive breast cancer［J］.Chongqing Medical Journal,2018,47（33):4278-4281.
［40］JOYCE DP,KERIN MJ,DWYER RM.Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer［J］.International Journal of Cancer,2016,139(7)：1443-1448.
［41］安学凤,李姝君,俞作仁,等.血清hsa-miR-486-5p在乳腺癌早期诊断中的价值［J］.同济大学学报(医学版),2018,39（3):1-6. AN XF,LI SJ,YU ZR,et al.The value of serum hsa-miR-486-5p in early diagnosis of breast cancer［J］.Journal of Tongji University（Medical Edition),2018,39（3):1-6.
［42］焦东晓,乔敏,吕复君,等.乳腺癌组织中miR-199b-5p、miR-597的表达及临床意义［J］.临床与实验病理学杂志,2018,34(10):1109-1114. JIAO DX,QIAO M,LYU FJ,et al.Expression and clinical significance of mir-199b-5p and mir-597 in breast cancer［J］.Journal of Clinical and Experimental Pathology,2018,34（10):1109-1114.
［43］NG EK,NG EK,LI R,et al.Circulating microRNAs as specific biomarkers for breast cancer detection［J］.PLoS One,2018,8(1)：e53141.
［44］吴欢,王晓林.白细胞、血小板、C-反应蛋白、降钙素原检测诊断新生儿感染性疾病的研究进展［J］.中国当代医药,2020,27(11):31-34. WU H,WANG XL.Research progress in the detection of leukocytes,platelets,C-reactive protein and procalcitonin in the diagnosis of neonatal infectious diseases［J］.Contemporary Chinese Medicine,2020,27（11):31-34.
［45］FELLER SM,LEWITZKY M.Hunting for the ultimate liquid cancer biopsy-let the TEP dance begin［J］.Cell Communication and Signaling,2016,14(1)：24.
［46］HEEKE S,MOGRABI B,ALIX-PANABIERES C,et al.Never travel alone:The crosstalk of circulating tumor cells and the blood microenvironment［J］.Cells,2019,8(7):714.
［47］ASGHAR S,PARVAIZ F,MANZOOR S.Multifaceted role of cancer educated platelets in survival of cancer cells［J］.Thrombosis Research,2019,177：42-50.
［48］LIU L,LIN F,MA X,et al.Tumor-educated platelet as liquid biopsy in lung cancer patients［J］.Critical Reviews in Oncology/Hematology,2020,146:102863.
［49］BEST MG,SOL N,KOOI I,et al.RNA-seq of tumor-educated platelets enables blood-based pan-cancer,multiclass,and molecular pathway cancer diagnostics［J］.Cancer Cell,2015,28(5):666-676.
［50］LIEFAARD MC,LIPS E,BEST M,et al.RNA signatures from tumor-educated platelets（TEP) enable detection of early-stage breast cancer［J］.Annals of Oncology,2019,30(Supl.3):iii13.

Memo

Memo:
-
Last Update: 2023-08-31